Immune Response Biopharma, Inc. (c) 2010-2019

 

Press Releases TM

Immune Response BioPharma, Inc. Remune BLA for Adults Update Files FDA FDRR Formal Dispute Resolution Request for Arbitration of Approval for Remune, if Necessary IRBP  Warns the FDA that IRBP will Seek Relief in Federal District Court,  IRBP Confident Remune will be Approved the Easy Way or the Hard Way, IRBP to make Remune Available for Right to Try Use 

April 7th 2018

 

Immune Response BioPharma, Inc. Remune Pediatric BLA  Update Pending to be Filed Under Protest FDA PDFUA Date TBD TBA

April 7th 2018

 

Immune Response BioPharma, Inc. Applauds Passage of House Bill & Endorses Congressional Federal Right to Try Bill Legislation 

April 7th 2018

 

Immune Response BioPharma, Inc. Enterprise fair value North of $15B HIV & MS Portfolio 5X Peak Sales of pipeline $3-5B annually

March 1st 2018

 

Immune Response BioPharma, Inc. NeuroVax Revenues range $54-108M on First Year Right to Try 

Compassionate Care Use MS Vaccine Pricing Cost Cap at estimated $3k per Injection

March 1st 2018

 

Immune Response BioPharma, Inc. Remune Revenues seen at $36-72M on First Year of Right to Try Compassionate Care Use of Remune HIV Vaccine Pricing Cost Cap at Approximately $3000 per Injection

Feb 17th 2018

Immune Response BioPharma, Inc.TM Copyright (C) 2010-2019  All Rights Reserved     www.immuneresponse.net